To examine the cytotoxicity of 2-ethoxystypandrone (1) against HCC cancer cell lines possessing different levels of basal activation of STAT3, we used a panel of HCC cells such as HepG2, HepG3B, SK-HEP-1, Li-7 and Huh-7, and found that 2-ethoxystypandrone (1) inhibited cell growth/survival more potently in human Li-7 and Huh-7 cancer cells (which contain constitutively activated STAT3, IC50 = 5.58 ± 0.89 μM and 3.69 ± 0.51μM, respectively) [27], as compared to those cells lacked aberrant STAT3 activation (IC50 = 16.71 ± 0.58 μM and 20.36 ± 2.90 μM, respectively). Here, STAT3 is linked to hepatocellular carcinoma.